prikaz prve stranice dokumenta Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
  Preuzmi
PDF 1.81 MB
Znanstveni rad - Izvorni znanstveni rad
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
British Journal of Clinical Pharmacology, 88 (2022), 5; 2065-2073. https://doi.org/10.1111/bcp.15126
Čalušić, Martina; Marčec, Robert; Lukša, Lea; Jurković, Ivan; Kovač, Nataša; Mihaljević, Slobodan; Likić, Robert

Citirajte ovaj rad

Čalušić, M., Marčec, R., Lukša, L., Jurković, I., Kovač, N., Mihaljević, S. i Likić, R. (2022). Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology, 88. (5), 2065-2073. doi: 10.1111/bcp.15126

Čalušić, Martina, et al. "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls." British Journal of Clinical Pharmacology, vol. 88, br. 5, 2022, str. 2065-2073. https://doi.org/10.1111/bcp.15126

Čalušić, Martina, Robert Marčec, Lea Lukša, Ivan Jurković, Nataša Kovač, Slobodan Mihaljević i Robert Likić. "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls." British Journal of Clinical Pharmacology 88, br. 5 (2022): 2065-2073. https://doi.org/10.1111/bcp.15126

Čalušić, M., et al. (2022) 'Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls', British Journal of Clinical Pharmacology, 88(5), str. 2065-2073. doi: 10.1111/bcp.15126

Čalušić M, Marčec R, Lukša L, Jurković I, Kovač N, Mihaljević S, i sur.. Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls. British Journal of Clinical Pharmacology [Internet]. 05.2022. [pristupljeno 11.04.2024.];88(5):2065-2073. doi: 10.1111/bcp.15126

M. Čalušić, et al., "Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls", British Journal of Clinical Pharmacology, vol. 88, br. 5, str. 2065-2073, Svibanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:224631. [Citirano: 11.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:224631
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls
AutorMartina Čalušić
AutorRobert Marčec
AutorLea Lukša
AutorIvan Jurković
AutorNataša Kovač
AutorSlobodan Mihaljević
AutorRobert Likić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA ANESTEZIOLOGIJU, REANIMATOLOGIJU I INTENZIVNU MEDICINU KIRURŠKIH STRUKA)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Anesteziologija i reanimatologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Aims: Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in three trials. The aim of this study was to evaluate the safety and efficacy of fluvoxamine in COVID-19 patients if administered later in the course of the disease. ----- Methods: The study was designed as an open-label, prospective cohort trial with matched controls. In April and May 2021, 51 ICU COVID-19 patients hospitalised in the University Hospital Dubrava and University Hospital Centre Zagreb, Croatia, were treated with fluvoxamine 100 mg three times daily for 15 days in addition to standard therapy and they were prospectively matched for age, gender, vaccination against COVID-19, disease severity and comorbidities with 51 ICU controls. ----- Results: No statistically significant differences between groups were observed regarding the number of days on ventilator support, duration of ICU or total hospital stay. However, overall mortality was lower in the fluvoxamine group, 58.8% (n = 30/51), than in the control group, 76.5% (n = 39/51), HR 0.58, 95% CI (0.36-0.94, P = .027). ----- Conclusion: Fluvoxamine treatment in addition to the standard therapy in hospitalised ICU COVID-19 patients could have a positive impact on patient survival. Further studies on the effects of fluvoxamine in COVID-19 patients are urgently required.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBritish Journal of Clinical Pharmacology
Brojčani podacivol. 88, br. 5, str. 2065-2073
p-ISSN0306-5251
e-ISSN1365-2125
DOIhttps://doi.org/10.1111/bcp.15126
URN:NBNurn:nbn:hr:105:224631
Datum objave publikacije2022-05
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1111/bcp.15126
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-06-28 07:27:42